I
InnoSkel
Biotech & Life Sciences · Valbonne, France · Founded 2020
A pioneering biotechnology company developing therapies for rare skeletal diseases MoreLess
Innoskel is a pioneering biotech startup based in Sophia Antipolis Bioparc, Nice, France, dedicated to transforming the lives of patients suffering from severe rare bone disorders. The company focuses on developing innovative gene therapies specifically targeting type II collagen disorders, a group of diseases that significantly impact bone health and quality of life.
Innoskel serves a niche market of underserved patient populations who have limited treatment options for their debilitating conditions. By leveraging its proprietary technology platform, Innoskel aims to create effective and groundbreaking treatments that address the root causes of these rare bone disorders. The company's approach is deeply patient-centric, emphasizing scientific innovation and operational excellence to achieve its mission.
The business model of Innoskel revolves around research and development (R&D) in gene therapy. The company collaborates with leading clinical research institutions to advance its therapeutic solutions from the lab to clinical trials and, eventually, to market. Innoskel generates revenue through a combination of funding from healthcare investors, partnerships, and potential future sales of its gene therapy products once they receive regulatory approval.
Innoskel's financial health is bolstered by strong backing from prominent healthcare investors who are committed to transforming biomedical research into viable therapies. This support has enabled the company to complete a Series A funding round, providing the necessary capital to advance its clinical studies and expand its R&D capabilities.
In summary, Innoskel is at the forefront of developing gene therapies for rare bone disorders, serving a critical need in the healthcare market. The company’s innovative approach, strong financial backing, and strategic partnerships position it well for future growth and success.
Keywords: biotech, gene therapy, rare bone disorders, type II collagen, patient-centric, innovation, clinical research, healthcare investors, R&D, Sophia Antipolis.
Company overview
InnoSkel company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2020
- Headquarters
- Valbonne, France
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 61.3
Valuation & funding
InnoSkel funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2020 | $22M | $88M | Vida Ventures · Turenne Capital · Région Sud Investissement · Jeito Capital | — |
| SPINOUT✓Other financing | Aug 2020 | — | — | French National Centre for Scientific Research - CNRS · INSERM · CNRS Innovation | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 1 |
| 2025 | 2 |
| 2024 | 7 |
| 2023 | 26 |
| 2022 | 28 |
Growth signals
InnoSkel website traffic
Latest recorded traffic for InnoSkel is 1K monthly website visits, up 16.3% over the last three months. InnoSkel's team declined 50% over the past year.
Comparisons
InnoSkel compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
InnoSkel's talent
Source: Dealroom Talent Intelligence.
Investors
7 investors on InnoSkel's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where InnoSkel has talent and traffic
In the news
Latest news about InnoSkel
Recent press, funding announcements, and product moves mentioning InnoSkel — open to read from the original sources.
Market sentiment
What the market is saying about InnoSkel
An AI-synthesized read of the highest-engagement posts about InnoSkel on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InnoSkel’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.